In addition, we observed slightly higher numbers of Trp2-specific CD8+ T cells in pooled tumor-draining lymph node samples from PeptiCRAd VALO-mD901-Trp2-treated mice compared to mock- or VALO-mD901-treated tumors (Figure 5B). The gene discussed is CD8A; the disease is neoplasm.